Innate Pharma 2022 Financial Calendar

Rhea-AI Summary

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced its 2022 financial calendar, detailing key dates for financial statement publications. Significant dates include the release of 2021 financial statements on March 24, 2022, Q1 2022 revenue on May 10, 2022, and half-year financials on September 15, 2022. The Annual General Shareholders Meeting is scheduled for May 20, 2022. All reports will be issued before market open CET. Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system for cancer treatment, with partnerships with notable industry leaders.

Positive

• Detailed financial calendar enhances transparency for investors.
• Strong partnerships with industry leaders such as Bristol-Myers Squibb and AstraZeneca provide strategic advantages in drug development.

Negative

• None.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2022 financial calendar:

March 24, 2022:		Publication of 2021 financial statements
May 10, 2022:		Publication of revenue for 1Q2022
May 20, 2022:		Annual General Shareholders Meeting
September 15, 2022:		Publication of half year financial statements
November 14, 2022:		Publication of revenue for 3Q2022

All financial reports are released before market open CET.

All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005451/en/

For additional information, please contact:



Investors



Innate Pharma

Henry Wheeler

Tel.: +33 761 88 38 74

Henry.wheeler@innate-pharma.fr



Media



Innate Pharma

Tracy Rossin (Global/US)

Tel.: +1 240 801 0076

Tracy.Rossin@innate-pharma.com



ATCG Press

Marie Puvieux (France)

Tel.: +33 (0)9 81 87 46 72

innate-pharma@atcg-partners.com

Source: Innate Pharma SA

FAQ

What is the financial calendar for Innate Pharma in 2022?

Innate Pharma's 2022 financial calendar includes dates for financial statements: March 24 for 2021 financials, May 10 for Q1 2022 revenue, May 20 for the Annual General Shareholders Meeting, September 15 for half-year financials, and November 14 for Q3 2022 revenue.

What is the primary focus of Innate Pharma?

Innate Pharma specializes in oncology, developing therapeutic antibodies that utilize the immune system to combat cancer.

What partnerships does Innate Pharma have?

Innate Pharma has significant alliances with companies like Bristol-Myers Squibb, Novo Nordisk, Sanofi, and AstraZeneca.

Where is Innate Pharma headquartered?

Innate Pharma is headquartered in Marseille, France, with a U.S. office in Rockville, MD.

What stock exchanges is Innate Pharma listed on?

Innate Pharma is listed on Euronext Paris and Nasdaq under the ticker symbol IPHA.